Restricted accessResearch articleFirst published online 2020-03
Evaluation of the Presence and Characterization of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Level Resistance Among Bloodstream Isolates of Methicillin-Resistant Staphylococcus aureus
Heterogeneous vancomycin-intermediate Staphylococcus aureus(hVISA) could be misinterpreted as “susceptible” with routine susceptibility testing procedures, and the subpopulations with reduced susceptibility to glycopeptides can lead to therapeutic failure. The aim of this study was to evaluate the presence of VISA and hVISA strains among stocked bloodstream methicillin-resistant S. aureus (MRSA) isolates of 14 years.
Materials and Methods:
A total of 127 nonduplicate MRSA strains isolated from blood cultures between 2001 and 2014 were investigated. Glycopeptide minimum inhibitory concentration values were detected by microbroth dilution method. Susceptibilities to other antimicrobials were determined by the disk diffusion method and interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria. Macrogradient test (MGT) and modified population analysis profile-area under the curve (modified PAP-AUC) methods were used to detect VISA and hVISA. Staphylococcal Cassette Chromosome mec (SCCmec), agr, and toxin gene typing were done by polymerase chain reaction. Genetic relatedness of the strains were evaluated by pulsed-field gel electrophoresis (PFGE).
Results:
All isolates were susceptible to glycopeptides, linezolid, and quinupristin-dalfopristin. All were resistant to tetracycline, 96% were resistant to aminoglycosides, fluoroquinolones, and rifampin. Only 58.3% of the isolates were susceptible to ceftaroline. Six isolates were suspected as hVISA by the MGT, but none could be confirmed by the modified PAP-AUC analysis. All isolates carried type-III SCCmec, sea was the most prevalent (96.9%) enterotoxin gene and agr group I locus was predominant (93.7%). PFGE analysis revealed four main and four unique patterns.
Conclusion:
No hVISA or VISA were detected. The resistance rate to ceftaroline seems remarkable due to its recent entry into the market in Turkey.
Get full access to this article
View all access options for this article.
References
1.
European Centre for Disease Prevention and Control (ECDC). 2017. Surveillance of antimicrobial resistance in Europe 2016. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm. Available at https://ecdc.europa.eu/sites/portal/files/documents/AMR-surveillance-Europe-2016.pdf (last accessed September25, 2016).
2.
Laupland, K.B. 2013. Incidence of bloodstream infection: a review of population-based studies. Clin. Microbiol. Infect. 19:492–500.
3.
SkinnerD., and KeeferC.S.. 1941. Significance of bacteremia caused by Staphylococcus aureus: a study of one hundred and twenty-two cases and a review of the literature concerned with experimental infection in animals. Arch. Intern. Med. 68:851–875.
4.
RammelkampC.H., and MaxonT.. 1942. Resistance of Staphylococcus aureus to the action of penicillin. Exp. Biol. Med. 51:386–389.
5.
The European Committee on Antimicrobial Susceptibility Testing (EUCAST). 2018. Breakpoint tables for interpretation of MICs and zone diameters. Version 8.1. Available at www.eucast.org/clinical_breakpoints/ (last accessed March7, 2018).
6.
KatayamaY., ItoT., and HiramatsuK.. 2000. A new class of genetic element, staphylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 44:1549–1555.
7.
BaigS., JohannesenT.B, Overballe-PetersenS., LarsenJ., LarsenA.R, and SteggerM.. 2018. Novel SCCmec type XIII (9A) identified in an ST152 methicillin-resistant Staphylococcus aureus. Infect. Genet. Evol. 61:74–76.
8.
AhmadN., RuzanI.N, Abd GhaniM.K, HussinA., NawiS., AzizM.N, ManingN., and EowV.L.. 2009. Characteristics of community- and hospital-acquired meticillin-resistant Staphylococcus aureus strains carrying SCCmec type IV isolated in Malaysia. J. Med. Microbiol. 58:1213–1218.
9.
KarahanZ.C., TekeliA., AdaletiR., KoyuncuE., DolapciI., and AkanO.A.. 2008. Investigation of Panton-Valentine leukocidin genes and SCCmec types in clinical Staphylococcus aureus isolates from Turkey. Microb. Drug Resist. 14:203–210.
10.
NguyenA.T., and TallentS.M.. 2018. From commensal to consumer: Staphylococcus aureus toxins, diseases, and detection methods. J. AOAC Int. 101:1127–1134.
11.
Novick, R.P. 2000. Pathogenicity factors and their regulation. In V.A. Fischetti, R.P. Novick, J.J. Ferretti, D.A. Portnoy, and J.I. Rood (ed.), Gram-positive pathogens. MBio, Washington,, D.C., pp. 392–407.
12.
LiuC., BayerA., CosgroveS.E, DaumR.S, FridkinS.K, GorwitzR.J, KaplanS.L, KarchmerA.W, LevineD.P, MurrayB.E, RybakM. J, TalanD.A, ChambersH.F, Infectious Diseases Society of America. 2011. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin. Infect. Dis. 52:e18–e55.
13.
HowdenB.P., DaviesJ.K, JohnsonP.D, StinearT.P, and GraysonM.L.. 2010. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin. Microbiol. Rev. 23:99–139.
14.
HiramatsuK., AritakaN., HanakiH., KawasakiS., HosodaY., HoriS., FukuchiY., and KobayashiI.. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet. 350:1670–1673.
15.
HiramatsuK., HanakiH., InoT., YabutaK., OguriT., and TenoverF.C.. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135–136.
Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. 27th Ed. CLSI Supplement M100. CLSI, Wayne, USA, 2017.
18.
HanakiH., and HiramatsuK.. 2001. Detection methods of glycopeptide-resistant Staphylococcus aureus I: susceptibility testing. Methods Mol. Med. 48:85–91.
19.
KhatibR., RiedererK., SharmaM., ShemesS., IyerS.P, and SzpunarS.. 2015. Screening for intermediately vancomycin-susceptible and vancomycin-heteroresistant Staphylococcus aureus by use of vancomycin-supplemented brain heart infusion agar biplates: defining growth interpretation criteria based on gold standard confirmation. J. Clin. Microbiol. 53:3543–3546.
20.
TekeliA., KoyuncuE., DolapciI., AkanO.A, and KarahanZ.C.. 2009. [Molecular characteristics of methicillin-resistant Staphylococcus aureus strains isolated from blood cultures between 2002–2005 in Ankara University Hospital]. Mikrobiyol. Bul. 43:1–10.
21.
TekeliA., OcalD.N, OzmenB.B, KarahanZ.C, and DolapciI.. 2016. Molecular characterization of methicillin-resistant Staphylococcus aureus bloodstream isolates in a Turkish University Hospital between 2002 and 2012. Microb. Drug Resist. 22:564–569.
22.
Clinical and Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M07-A9. 9th Ed. CLSI, USA, 2012.
23.
WoottonM., MacGowanA.P, WalshT.R, and HoweR.A.. 2007. A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. J. Clin. Microbiol. 45:329–332.
24.
WoottonM., HoweR.A, HillmanR., WalshT.R, BennettP.M, and MacGowanA.P.. 2001. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J. Antimicrob. Chemother. 47:399–403.
25.
ArajG.F., TalhoukR.S, SimaanC.J, and MaasadM.J.. 1999. Discrepancies between mecA PCR and conventional tests used for detection of methicillin resistant Staphylococcus aureus. Int. J. Antimicrob. Agents. 11:47–52.
26.
KondoY., ItoT., MaX.X, WatanabeS., KreiswirthB.N, EtienneJ., and HiramatsuK.. 2007. Combination of multiplex PCRs for staphylococcal cassette chromosome mec type assignment: rapid identification system for mec, ccr, and major differences in junkyard regions. Antimicrob. Agents Chemother. 51:264–274.
27.
GilotP., LinaG., CochardT., and PoutrelB.. 2002. Analysis of the genetic variability of genes encoding the RNA III-activating components Agr and TRAP in a population of Staphylococcus aureus strains isolated from cows with mastitis. J. Clin. Microbiol. 40:4060–4067.
28.
MondayS.R., and BohachG.A.. 1999. Use of multiplex PCR to detect classical and newly described pyrogenic toxin genes in staphylococcal isolates. J. Clin. Microbiol. 37:3411–3414.
29.
MulveyM.R., ChuiL., IsmailJ., LouieL., MurphyC., ChangN., AlfaM., and Canadian Committee for the Standardization of MolecularM.2001. Development of a Canadian standardized protocol for subtyping methicillin-resistant Staphylococcus aureus using pulsed-field gel electrophoresis. J. Clin. Microbiol. 39:3481–3485.
30.
AtmacaO., ZarakoluP., KarahanC., CakirB., and UnalS.. 2014. [Risk factors and antibiotic use in methicillin-resistant Staphylococcus aureus bacteremia in hospitalized patients at Hacettepe University Adult and Oncology Hospitals (2004–2011) and antimicrobial susceptibilities of the isolates: a nested case-control study]. Mikrobiyol. Bul. 48:523–537.
31.
ZarakoluP., MetanG., UnalS., KarahanZ.C, and TekeliA.. 2016. Bacterial factors influencing the mortality for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. Infect. Dis. (Lond), 48:649–650.
AlmR.A., McLaughlinR.E, KosV.N, SaderH.S, IaconisJ.P, and LahiriS.D.. 2014. Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective. J. Antimicrob. Chemother. 69:2065–2075.
34.
AndreyD.O., FrancoisP., ManzanoC., BonettiE.J, HarbarthS., SchrenzelJ., KelleyW.L, and RenzoniA.. 2017. Antimicrobial activity of ceftaroline against methicillin-resistant Staphylococcus aureus (MRSA) isolates collected in 2013–2014 at the Geneva University Hospitals. Eur. J. Clin. Microbiol. Infect. Dis. 36:343–350.
35.
SaderH.S., MendesR.E, JonesR.N, and FlammR.K.. 2016. Antimicrobial susceptibility patterns of community- and hospital-acquired methicillin-resistant Staphylococcus aureus from United States Hospitals: results from the AWARE Ceftaroline Surveillance Program (2012–2014). Diagn. Microbiol. Infect. Dis. 86:76–79.
36.
Centers for Disease Control, and Prevention. 2002. Staphylococcus aureus resistant to vancomycin—United States, 2002. MMWR Morb. Mortal. Wkly. Rep. 51:565–567.
37.
MirzaH.C., SancakB., and GurD. 2015. The prevalence of vancomycin-intermediate Staphylococcus aureus and heterogeneous VISA among methicillin-resistant strains isolated from pediatric population in a Turkish University Hospital. Microb. Drug Resist. 21:537–544.
38.
RichterS.S., SatolaS.W, CrispellE.K., HeilmannK.P, DohrnC.L, RiahiF., CostelloA.J, DiekemaD.J, and DoernG.V.. 2011. Detection of Staphylococcus aureus isolates with heterogeneous intermediate-level resistance to vancomycin in the United States. J. Clin. Microbiol. 49:4203–4207.
39.
YilmazS., KilicA., KaragozA., BedirO., Uskudar GucluA., and BasustaogluA.C. 2012. [Investigation of various virulence factors among the hospital and community-acquired Staphylococcus aureus isolates by real-time PCR method]. Mikrobiyol. Bul. 46:532–545.
40.
GoudarziM., SeyedjavadiS.S, NasiriM.J, GoudarziH., Sajadi NiaR., and DabiriH.. 2017. Molecular characteristics of methicillin-resistant Staphylococcus aureus (MRSA) strains isolated from patients with bacteremia based on MLST, SCCmec, spa, and agr locus types analysis. Microb. Pathog. 104:328–335.
41.
SakoulasG., EliopoulosG.M, MoelleringR.CJr., WennerstenC., VenkataramanL., NovickR.P, and GoldH.S.. 2002. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob. Agents Chemother. 46:1492–1502.
42.
HoweR.A., MonkA., WoottonM., WalshT.R, and EnrightM.C.. 2004. Vancomycin susceptibility within methicillin-resistant Staphylococcus aureus lineages. Emerg. Infect. Dis. 10:855–857.
43.
Ghaznavi-RadE., Nor ShamsudinM., SekawiZ., KhoonL.Y, AzizM.N, HamatR.A, OthmanN., ChongP.P, van BelkumA., Ghasemzadeh-MoghaddamH., and NeelaV.. 2010. Predominance and emergence of clones of hospital-acquired methicillin-resistant Staphylococcus aureus in Malaysia. J. Clin. Microbiol. 48:867–872.
44.
DmitrenkoO.A., ProkhorovV., FluerF.S, SuborovaT.N, VolkovI.I, KarabakV.I, and GintsburgA.L.. 2006. [Detection of the genes of pyrogenic toxins of superantigens in clinical isolates of methicillin resistant Staphylococcus aureus]. Zh. Mikrobiol. Epidemiol. Immunobiol. 2:36–42.
45.
Kirca YilmazS., AcunerI.C, StrommengerB., BekY., and WitteW.. 2014. [Infectivity-resistotype-genotype clustering of methicillin-resistant Staphylococcus aureus strains in the Central Blacksea Region of Turkey]. Mikrobiyol. Bul. 48:14–27.
46.
OksuzL., DupieuxC., TristanA., BesM., EtienneJ., and GurlerN.. 2013. The high diversity of MRSA clones detected in a university hospital in Istanbul. Int. J. Med. Sci. 10:1740–1745.
47.
HuH.C., KaoK.C, ChiuL.C, ChangC.H, HungC.Y, LiL.F, LiuT.P, LinL.C, ChenN.H, HuangC.C, YangC.T, and LuJ.J.. 2015. Clinical outcomes and molecular typing of heterogenous vancomycin-intermediate Staphylococcus aureus bacteremia in patients in intensive care units. BMC Infect. Dis. 15:444.
